Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515).
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitive radiotherapy in combination with cemiplimab-rwlc for locally advanced, unresectable cutaneous squamous cell carcinoma (CSCC) (Abstract 9506).
Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III Alliance A081105 trial, which evaluated adjuvant erlotinib vs observation after complete resection of EGFR-mutant non–small cell lung cancer (NSCLC) (Abstract 8001).
Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, adjuvant pembrolizumab for 1 year approximately doubled disease-free survival, causes fatigue and dyspnea which modestly impacted physical function and ability to perform certain roles (such as work and hobbies), without impact on overall quality of life (Abstract 4513).
Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy (ADT) vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer (Abstract LBA1).
Jana de Boniface, MD, PhD, of Capio Saint Göran's Hospital and Karolinska Institutet, reviews overall survival and patient-reported arm morbidity findings from the SENOMAC trial, which sought to determine if patients with breast cancer and sentinel lymph node macrometastases could omit complete axillary dissection (Abstract LBA503).
